Skip to main content


Breast Cancer

Featured

Conference Coverage
A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus…
Conference Coverage
Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS…
Conference Coverage
Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs…
Videos
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy…
Quiz
True or False: Adjuvant hormonal therapy adherence at 5 years are low among commercially insured patients with breast…
Back to Top